3 New Strong Buy Ratings from Top-Rated Analysts: 08/12/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Arcutis Biotherapeutics (ARQT): Revenue soars on dermatology franchise strength 
• PTC Therapeutics (PTCT): Seven Strong Buys on rare disease leader
• Banco Macro (BMA): Argentina's #1 rated bank with big upside potential 

P.S. Want more timely stock picks? Check this out. 

A note from our sponsors...

Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile's Regulation A+ Offering.

1. Arcutis Biotherapeutics (NASDAQ: ARQT)

Led by its flagship ZORYVE dermatological franchise, the company recently reported strong Q2 results with revenue beating estimates by 6.57% and growing 59% year-over-year, positioning it for continued growth through the second half of 2026.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $25.29 — get current quote

Max 1-year forecast: $40.00

Why we're watching:

• ARQT has solid, bullish coverage among the analysts we track, with 3 Strong Buy and 3 Buy recommendations. See all recommendations here
• For example, Guggenheim researcher Seamus Fernandez (a top 2% rated analyst) maintained his Strong Buy rating with a price target representing 50% upside potential from current levels, following the company's strong Q2 print that prompted raised estimates on Zoryve.
• Likewise, Needham researcher Serge Belanger (a top 2% rated analyst) maintained his Buy rating with a price target representing 58% upside potential from current levels.
• Three additional top analysts covering ARQT all maintain bullish outlooks on the dermatology franchise's growth.
• Q2 earnings demonstrated execution strength: EPS of $0.11 with -15.4% year-over-year growth, while revenue of $129.86M exceeded expectations by 6.57% with 59% YoY growth.
• Zen Ratings highlights: ARQT earns an overall A rating, equal to a Strong Buy recommendation. Stocks in this elite tier have historically delivered nearly 30% annual returns, significantly outperforming the S&P.
• Component Grades: ARQT shows strong Bs for Financials, Growth, Sentiment, and Value, reflecting the company's robust product pipeline and expanding market opportunities in dermatology therapeutics. See all 7 Component Grades here

2. PTC Therapeutics (NASDAQ: PTCT)

This biopharma company focuses on rare genetic disorders. With strong pipeline momentum and robust analyst support, the company is positioned to capitalize on growing demand across its rare disease portfolio.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $73.31 — get current quote

Max 1-year forecast: $130.00

Why we're watching:

• PTCT has strong, bullish coverage among the analysts we track, with 7 Strong Buy and 1 Hold recommendations. See all recommendations here
• For example, Cantor Fitzgerald researcher Kristen Kluska (a top 3% rated analyst) maintained her Strong Buy recommendation with a price target representing 77% upside potential from current levels.
• Additionally, Citigroup researcher Geoff Meacham (a top 8% rated analyst) assumed coverage with a Strong Buy recommendation and a price target representing 47% upside potential from current levels.  
• Zen Ratings highlights: PTCT earns an overall A rating, which amounts to a Strong Buy recommendation. This letter grade reflects a stock that has passed a rigorous 115-factor fundamental review, placing it among the elite top 5% of all stocks tracked.
• Component Grades: PTCT stands out with an A for Growth and solid Bs for Momentum and Sentiment, signaling strong market confidence in the company's pipeline development and commercial expansion strategy. See all 7 Component Grades here

3. Macro Bank (NYSE: BMA)

Macro Bank is a leading private bank in Argentina serving retail customers and small businesses. The bank's strong positioning in the Argentine market and its diversified service offerings present compelling growth opportunities as the regional economy continues to develop.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $83.65 — get current quote

Max 1-year forecast: $132.00

Why we're watching:

• BMA has limited, but overall bullish, coverage among the analysts we track, with 3 Strong Buy recommendations. See all recommendations here
• For example, JP Morgan researcher Yuri Fernandes (a top 21% rated analyst) maintained his Strong Buy recommendation with a price target representing 58% upside potential from current levels.
• Industry ranking context: BMA is currently the #1 highest-rated stock in the Bank industry, though it’s worth noting that the industry currently carries a D rating.
• Zen Ratings highlights: BMA receives an overall A rating, equal to a Strong Buy recommendation. Stocks with this rating represent the topmost tier based on our comprehensive 115-factor analysis, historically delivering nearly 30% per year.
• Component Grades: BMA excels with an A for Artificial Intelligence and strong Bs for Growth, Momentum, and Sentiment, reflecting the bank's innovation initiatives and strong market positioning in Argentina's evolving financial landscape. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.